Prudential Financial Inc. Has $13.47 Million Stake in The Cooper Companies, Inc. (NASDAQ:COO)

Prudential Financial Inc. cut its stake in shares of The Cooper Companies, Inc. (NASDAQ:COO) by 39.3% during the 4th quarter, Holdings Channel reports. The institutional investor owned 146,478 shares of the medical device company’s stock after selling 94,658 shares during the quarter. Prudential Financial Inc.’s holdings in Cooper Companies were worth $13,466,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in COO. Raymond James Financial Inc. acquired a new position in shares of Cooper Companies in the fourth quarter worth approximately $64,826,000. Victory Capital Management Inc. boosted its stake in shares of Cooper Companies by 14.6% in the 4th quarter. Victory Capital Management Inc. now owns 4,525,018 shares of the medical device company’s stock valued at $415,985,000 after purchasing an additional 574,899 shares during the last quarter. JPMorgan Chase & Co. increased its position in shares of Cooper Companies by 13.2% during the third quarter. JPMorgan Chase & Co. now owns 4,930,022 shares of the medical device company’s stock worth $543,979,000 after buying an additional 573,908 shares during the period. Wealthfront Advisers LLC raised its stake in Cooper Companies by 4,594.1% during the fourth quarter. Wealthfront Advisers LLC now owns 569,812 shares of the medical device company’s stock worth $52,383,000 after buying an additional 557,673 shares during the last quarter. Finally, Alecta Tjanstepension Omsesidigt bought a new position in Cooper Companies during the fourth quarter worth $49,550,000. Institutional investors own 24.39% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have weighed in on the company. StockNews.com downgraded Cooper Companies from a “buy” rating to a “hold” rating in a report on Wednesday, December 11th. Stifel Nicolaus lowered their target price on Cooper Companies from $115.00 to $105.00 and set a “buy” rating for the company in a report on Friday, March 7th. Morgan Stanley dropped their price target on Cooper Companies from $104.00 to $102.00 and set an “equal weight” rating on the stock in a research note on Friday, December 6th. Wells Fargo & Company raised their price objective on shares of Cooper Companies from $115.00 to $118.00 and gave the stock an “overweight” rating in a research report on Friday, December 6th. Finally, Citigroup dropped their target price on shares of Cooper Companies from $115.00 to $110.00 and set a “buy” rating on the stock in a research report on Friday, March 7th. Four analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $110.25.

Cooper Companies Stock Performance

COO opened at $84.98 on Friday. The Cooper Companies, Inc. has a 1-year low of $77.05 and a 1-year high of $112.38. The company has a market cap of $16.99 billion, a price-to-earnings ratio of 43.58, a PEG ratio of 2.25 and a beta of 1.02. The company’s fifty day moving average price is $89.52 and its two-hundred day moving average price is $97.53. The company has a current ratio of 1.91, a quick ratio of 1.12 and a debt-to-equity ratio of 0.32.

Cooper Companies (NASDAQ:COO) last posted its earnings results on Thursday, March 6th. The medical device company reported $0.92 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.92. The company had revenue of $964.70 million for the quarter, compared to analyst estimates of $981.25 million. Cooper Companies had a net margin of 10.07% and a return on equity of 9.38%. On average, analysts expect that The Cooper Companies, Inc. will post 3.98 EPS for the current fiscal year.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.